<DOC>
	<DOCNO>NCT00453323</DOCNO>
	<brief_summary>Capecitabine orally administer fluoropyrimidine convert 5-FU thymidine phosphorylase ( TP ) , preferentially tumor tissue demonstrate activity single agent patient gastrointestinal cancer . Up-regulation TP taxane treatment vitro suggest may synergistic effect combine treatment taxane capecitabine . The combination taxane capecitabine report highly active non-small cell lung cancer , breast cancer , stomach cancer .</brief_summary>
	<brief_title>Paclitaxel Capecitabine Patients With Metastatic/Recurrence Esophageal Cancer</brief_title>
	<detailed_description>Paclitaxel-80 mg/m2/IV D1 &amp; D8 q 3 week Capecitabine-900 mg/m2/PO twice daily Days 1-14 q 3 week Patients receive treatment every 3 week till disease progression .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Histologically cytologically confirm esophageal cancer histology squamous carcinoma adenocarcinoma 2 . Clinically diagnosed metastatic recurrent esophageal cancer accord Sixth Edition AJCC Cancer Staging Manual ( Appendix V ) 3 . At least 18 year old 4 . Disease status must measurable disease define RECIST : Lesions accurately measure least one dimension &gt; 10 mm chest xray , spiral CT scan physical examination 5 . ECOG performance status 02 6 . No prior radiotherapy measurable lesion ( ) previous surgery and/or chest radiotherapy primary lesion allow 7 . Adequate major organ function include follow : Hematologic function : WBC ≥ 3,500/mm3 absolute neutrophil count ( ANC ) ≥ 1,500/mm3 , platelet count ≥ 100,000/mm3Hepatic function : bilirubin ≤ 1.5 x UNL , AST/ALT level ≤ 2.5 x UNLRenal function : serum creatinine ≤ 1.5mg/dL 8 . Patients sign inform consent 9 . If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method ( intrauterine device [ IUD ] , birth control pill , barrier device ) 3 month trial . If male , use approve contraceptive method study 3 month afterwards . Females childbearing potential must urine negative hCG test within 7 day prior study enrollment . 1 . MI within precede 6 month symptomatic heart disease include unstable angina , congestive heart failure , uncontrolled arrhythmia 2 . Serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy 3 . Pregnant nursing woman 4 . Other malignancy past 5 year except adequately treat cutaneous basal cell carcinoma uterine cervix situ cancer 5 . Psychiatric disorder would preclude compliance . 6 . Major surgery biopsy within past two week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Phase II</keyword>
	<keyword>Metastatic esophageal cancer</keyword>
	<keyword>Recurrent esophageal cancer</keyword>
</DOC>